Improving the Therapeutic Index of Proinflammatory Cytokines for Cancer Immunotherapy Werewolf Therapeutics, Inc., is an ...

As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform In preclinical ...

Compass Therapeutics' tovecimig shows promise in biliary cancer, boasting a 17.1% response rate. Despite high risks, I ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Metastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge, with low 5-year survival rates and limited durable responses to existing therapies. While standard ...

This is important in the development of new therapeutics for cancers that have proven resistant to standard checkpoint therapies. We believe APVO711 has the potential to unlock deeper, more ...

Positive phase 3 results from the CAN-2409 clinical trial in intermediate-to-high risk localized prostate cancer have been ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 5.62%, which has investors questioning if this is right time to buy.